Potato-products group Agristo plans more India investment
The venture operates a facility in the Bijnor district of Uttar Pradesh.
In a statement, Belgium-based Agristo said since the facility's launch in 2022, potato yields in the region have nearly doubled from 17t per hectare (ha) to 32t per ha, marking 'one of the highest' yields in India.
Kristof Wallays, Agristo's director of international expansion, innovation, and sustainability, said: 'Our collaboration with Masa Global allows us to contribute to the rapidly growing Indian agriculture and food processing sector, benefiting all stakeholders involved.'
The Bijnor factory supplies customers in India and in export markets including the Middle East, South East Asia and North America.
The new investment will introduce a production line for frozen potato products, an 'important step in the company's ongoing growth', Agristo said.
Flemish Minister-President Matthias Diependaele said: 'With Flemish technology, we are building the future here [India].
'This investment not only strengthens the Indian economy but also fosters new innovations and closer cooperation with local farmers.'
In January, Agristo announced plans for its production facility in the US with a site in North Dakota.
The company is also expanding its production capacity in Europe to meet increasing demand.
It is expanding its site in Wielsbeke in Belgium, with preparatory work underway for a new plant in Escaudoeuvres in France.
"Potato-products group Agristo plans more India investment " was originally created and published by Just Food, a GlobalData owned brand.
The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Epoch Times
14 minutes ago
- Epoch Times
The Hidden Math That Makes Some Australians Poorer for Working Harder
AD It may seem counterintuitive, but working longer hours can make you less money, the e61 Institute says. A pile of bills in Brisbane, Australia, on Oct. 30, 2013. AAP Image/Dan Peled 8/13/2025 | Updated: 8/13/2025 Not so long ago, working harder was thought to guarantee you were better off. Rex Widerstrom is a New Zealand-based reporter with over 40 years of experience in media, including radio and print. He is currently a presenter for Hutt Radio. Author's Selected Articles
Business Upturn
17 minutes ago
- Business Upturn
Indoco Remedies gets USFDA nod for generic Rivaroxaban tablets; eyes growth in US Market
Mumbai-based Indoco Remedies Ltd. has secured final approval from the US Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) to market Rivaroxaban Tablets USP in strengths of 2.5 mg, 10 mg, 15 mg, and 20 mg. The product is the generic equivalent of Janssen Pharmaceuticals' blockbuster anticoagulant, Xarelto, and will be manufactured at Indoco's Verna, Goa facility. The approved Rivaroxaban tablets are bioequivalent and therapeutically equivalent to Xarelto and are indicated for the treatment of venous thromboembolism (VTE). This approval marks another milestone in Indoco's push into the US generics market, one of the most lucrative pharmaceutical markets globally. Commenting on the development, Indoco Remedies' Managing Director Aditi Panandikar said, 'Besides reflecting the capability of Indoco Remedies to deliver products of high-quality standards, this development also provides impetus to our growth aspirations in an important market such as the US.' Indoco Remedies is a fully integrated, research-driven pharmaceutical company with a global footprint, generating over 106 million prescriptions annually in India alone. The company operates 11 manufacturing facilities — seven for finished dosage forms (FDFs) and four for active pharmaceutical ingredients (APIs) — all of which are approved by top global regulatory agencies including the USFDA and UK-MHRA. With a turnover of $180 million and a workforce of more than 6,000 employees, Indoco is known for popular domestic brands such as Cyclopam, Febrex Plus, Sensodent-K, Karvol Plus, ATM, Oxipod, and Cital. Internationally, the company partners with large generics players to expand its market reach across multiple geographies. The latest USFDA approval strengthens Indoco's product portfolio in the regulated market and could open up significant revenue opportunities as Rivaroxaban continues to be a widely prescribed oral anticoagulant in the US. Disclaimer: This news article is for informational purposes only and does not constitute investment advice. Investors should consult a qualified financial advisor before making investment decisions. Ahmedabad Plane Crash Aditya Bhagchandani serves as the Senior Editor and Writer at Business Upturn, where he leads coverage across the Business, Finance, Corporate, and Stock Market segments. With a keen eye for detail and a commitment to journalistic integrity, he not only contributes insightful articles but also oversees editorial direction for the reporting team.
Business Upturn
2 hours ago
- Business Upturn
Honasa Consumer surges over 8% after Q1 earnings beat and brokerage upgrades
By Aditya Bhagchandani Published on August 13, 2025, 09:24 IST Shares of Honasa Consumer Ltd., the parent company of Mamaearth, surged 8.15% to ₹291.25 on Wednesday, August 13, following the announcement of its June quarter (Q1 FY26) results after market hours on Tuesday. This marks the second consecutive session of gains for the stock. The company posted a net profit of ₹41 crore for Q1 FY26, up 2.7% year-on-year, while revenue grew 7% YoY to ₹595 crore. EBITDA slipped 1% YoY to ₹46 crore, with margins holding at 7.7%. Hong Kong-based brokerage CLSA upgraded Honasa to 'Outperform' and raised its price target to ₹333, noting Q1 revenue growth of 7.4% YoY in line with expectations, alongside underlying volume growth of 10.5% YoY. CLSA highlighted a sequential EBITDA margin expansion of 264 bps to 7.7%, delivering a 47% beat versus its estimates and a 44% beat on consensus expectations. Management guided for an EBITDA margin of around 7% in FY26, with 100-150 bps expansion annually over the next 4–5 years. CLSA also raised its FY26–FY28 earnings estimates by 15–26%. Jefferies maintained a 'Buy' rating with a price target of ₹400, citing positive margin surprises. The brokerage acknowledged that unseasonal rains impacted sunscreen sales but noted that sequential EBITDA margin improvement and outperformance versus expectations were key positives. Jefferies added that while new brands are scaling slowly, Mamaearth remains the primary growth driver. Ahmedabad Plane Crash Aditya Bhagchandani serves as the Senior Editor and Writer at Business Upturn, where he leads coverage across the Business, Finance, Corporate, and Stock Market segments. With a keen eye for detail and a commitment to journalistic integrity, he not only contributes insightful articles but also oversees editorial direction for the reporting team.
